Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 458.0
(-2.35%)
JPY 458.0
(-2.35%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | 133.77 Million | 26.45 Million | -93.2 Million | -194.14 Million | -608 Million |
| Net Income | 124.64 Million | -280.61 Million | -250.14 Million | -310.63 Million | -668 Million |
| Depreciation & Amortization | 2.33 Million | - | - | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 27.31 Million | -47.62 Million | 8.51 Million | 14.83 Million | 2 Million |
| Other non-cash items | -8.16 Million | 30.95 Million | 46 Thousand | 18.72 Million | 58 Million |
| Investing Cash Flow | -24.49 Million | 30.03 Million | -155.62 Million | -17.23 Million | 10 Million |
| Investments in PPE | -18.66 Million | - | - | -13.46 Million | - |
| Acquisitions | - | 77.78 Million | 371 Thousand | -9.8 Million | 17 Million |
| Investment purchases | -62.16 Million | -62.16 Million | -62.16 Million | -62.16 Million | -62.16 Million |
| Sales/Maturities of investments | 56.16 Million | 68.16 Million | 56.16 Million | 68.16 Million | 56.15 Million |
| Other Investing Activities | 165 Thousand | 1.25 Million | -155 Million | 31 Thousand | -178 Thousand |
| Financing Cash Flow | 991 Thousand | 991 Thousand | 143.99 Million | -216 Million | 81 Million |
| Debt repayment | -992 Thousand | -992 Thousand | -143.99 Million | -216 Million | -385 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | -200 Million | 467.85 Million |
| Other Financing Activities | -1000.00 | -1000.00 | 105 Million | - | 466 Million |
| Accounts receivables | 32 Million | -49 Million | 25 Million | -27 Million | 37 Million |
| Accounts payables | -1.35 Million | 1.76 Million | -3.31 Million | 2.27 Million | 193 Thousand |
| Inventory | -3.89 Million | -6.32 Million | -15.61 Million | 33.81 Million | -7 Million |
| Other working capital | -17 Million | 35 Million | -2 Million | 44 Million | -28 Million |
| Cash at beginning of period | 561.99 Million | 449.18 Million | 552.02 Million | 974.45 Million | 1.49 Billion |
| Cash at end of period | 674.96 Million | 561.99 Million | 449.18 Million | 552.02 Million | -517 Million |
| Capital Expenditure | -18.66 Million | - | - | -13.46 Million | - |
| Effect of forex changes on cash | 2.7 Million | 2.08 Million | 1.99 Million | 4.94 Million | - |
| Net cash flow / Change in cash | 112.97 Million | 112.81 Million | -102.83 Million | -422.43 Million | -2 Billion |
| Free Cash Flow | 115.11 Million | 26.45 Million | -93.2 Million | -207.6 Million | -608 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 51 Million | 124.64 Million | 166 Million | -6 Million | 15 Million | 11 Million |
| Depreciation & Amortization | - | 2.33 Million | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 27.31 Million | - | - | - | - |
| Other non-cash items | -51 Million | -8.16 Million | -166 Million | 6 Million | -15 Million | -11 Million |
| Investing Cash Flow | - | -24.49 Million | - | - | - | - |
| Investments in PPE | - | -18.66 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -62.16 Million | - | - | - | - |
| Sales/Maturities of investments | - | 56.16 Million | - | - | - | - |
| Other Investing Activities | - | 165 Thousand | - | - | - | - |
| Financing Cash Flow | - | 991 Thousand | - | - | - | - |
| Debt repayment | - | -992 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -1000.00 | - | - | - | - |
| Accounts receivables | - | 32 Million | - | - | - | - |
| Accounts payables | - | -1.35 Million | - | - | - | - |
| Inventory | - | -3.89 Million | - | - | - | - |
| Other working capital | - | -17 Million | - | - | - | - |
| Cash at beginning of period | - | 561.99 Million | - | - | - | - |
| Cash at end of period | - | 674.96 Million | - | - | - | - |
| Capital Expenditure | - | -18.66 Million | - | - | - | - |
| Effect of forex changes on cash | - | 2.7 Million | - | - | - | - |
| Net cash flow / Change in cash | - | 112.97 Million | - | - | - | - |
| Free Cash Flow | - | 115.11 Million | - | - | - | - |
INPOY
4009
6573
6798
WKHS
SOMANYCERA